In young adults, grade 2 gliomas lead to progressive neurologic deterioration and premature death. Prior treatments with procarbazine, lomustine (also called as CCNU), and vincristine after radiation therapy revealed a longer progression-free survival, but not over-all survival. This synopsis reports the long-term results of procarbazine, CCNU, and vincristine in grade 2 glioma patients. In adults, grade 2 gliomas constitute 5 to 10% of all brain tumors.
Eventually, nearly all patients with developing symptoms die prematurely. Initial chemotherapy trials in this studies, caused tumor regression in patients with recurrent low-grade gliomas, with regimens that included procarbazine, lomustine (CCNU), and vincristine, carmustine (also called BCNU) plus interferon, and mechlorethamine, vincristine, and procarbazine. On the other hand, combined initial therapy with procarbazine, CCNU, and…
